Roundtable Discussion: Safety First: Approaching ADC Design & Development with a Tolerability-Led Philosophy to Widen Therapeutic Index & Benefit Patients
- Assessing the importance of safety-led ADC innovation to widen therapeutic index and maximize patient benefit
- Evaluating lessons learned from early development of ADCs: What can be done to improve tolerability and therapeutic index?
- Exploring the breadth of ADC innovation to widen therapeutic index across less potent payloads, conditionally active ADCs, and novel linker-payload chemistry